Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy
- PMID: 32846211
- DOI: 10.1016/j.phrs.2020.105164
Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy
Abstract
Epidermal growth factor receptor (EGFR), also known as ErbB-1/HER-1, plays a key role in the regulation of the cell proliferation, migration, differentiation, and survival. Since the constitutive activation or overexpression of EGFR is nearly found in various cancers, the applications focused on EGFR are the most widely used in the clinical level, including the therapeutic drugs of targeting EGFR, monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs).Over the past decades, the compounds from natural sources have been a productive source of novel drugs, especially in both discovery and development of anti-tumor drugs by targeting the EGFR pathways as the TKIs. This work presents a review of the compounds from natural sources as potential EGFR-TKIs involved in the regulation of cancer. Moreover, high-throughput drug screening of EGFR-TKIs from the natural compounds has also been summarized.
Keywords: Cancer; Epidermal growth factor receptor; High-throughput drug screening; Natural compounds; Tyrosine kinase inhibitor.
Copyright © 2020. Published by Elsevier Ltd.
Similar articles
-
Discovery of an EGFR tyrosine kinase inhibitor from Ilex latifolia in breast cancer therapy.Bioorg Med Chem Lett. 2019 Jun 1;29(11):1282-1290. doi: 10.1016/j.bmcl.2019.04.009. Epub 2019 Apr 4. Bioorg Med Chem Lett. 2019. PMID: 30962086
-
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.Bioorg Chem. 2020 Jun;99:103811. doi: 10.1016/j.bioorg.2020.103811. Epub 2020 Apr 2. Bioorg Chem. 2020. PMID: 32278207 Review.
-
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.Biomaterials. 2013 Nov;34(34):8690-707. doi: 10.1016/j.biomaterials.2013.07.100. Epub 2013 Aug 13. Biomaterials. 2013. PMID: 23953842 Review.
-
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.Curr Top Med Chem. 2020;20(10):815-834. doi: 10.2174/1568026620666200303123102. Curr Top Med Chem. 2020. PMID: 32124699 Review.
-
Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.Chem Pharm Bull (Tokyo). 2019 Aug 1;67(8):864-871. doi: 10.1248/cpb.c19-00300. Epub 2019 May 29. Chem Pharm Bull (Tokyo). 2019. PMID: 31142691
Cited by
-
Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma.iScience. 2023 May 5;26(6):106816. doi: 10.1016/j.isci.2023.106816. eCollection 2023 Jun 16. iScience. 2023. PMID: 37235052 Free PMC article. Review.
-
A New Series of Indeno[1,2-c]pyrazoles as EGFR TK Inhibitors for NSCLC Therapy.Molecules. 2022 Jan 13;27(2):485. doi: 10.3390/molecules27020485. Molecules. 2022. PMID: 35056800 Free PMC article.
-
New quinazoline-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of EGFR: synthesis, anti-breast cancer evaluation and in silico studies.RSC Med Chem. 2025 Jul 18. doi: 10.1039/d5md00103j. Online ahead of print. RSC Med Chem. 2025. PMID: 40689028 Free PMC article.
-
Emerging magic bullet: subcellular organelle-targeted cancer therapy.Med Rev (2021). 2024 Sep 12;5(2):117-138. doi: 10.1515/mr-2024-0044. eCollection 2025 Apr. Med Rev (2021). 2024. PMID: 40224364 Free PMC article. Review.
-
A momentous progress update: epidermal growth factor receptor inhibitors as viable agents for combating cancer.RSC Med Chem. 2025 Jul 7. doi: 10.1039/d4md00799a. Online ahead of print. RSC Med Chem. 2025. PMID: 40630673 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous